secwatch.observer — SEC 8-K summary
======================================

Issuer:     INNOVATE Corp. (VATE)
CIK:        0001006837
Form:       8-K
Filed at:   2026-03-26T23:59:59+00:00
Accession:  0001006837-26-000013
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INNOVATE Q4 rev surges 62% to $382.7M; net loss narrows to $7.8M; backlog $1.8B
-------------------------------------------------------------------------------

- Q4 revenue $382.7M (+61.7% YoY); net loss $7.8M ($0.58 EPS) vs $16.9M loss a year ago.
- FY 2025 revenue $1.246B (+12.5%); net loss $64.0M ($4.84 EPS) vs $35.8M loss in 2024.
- Q4 total Adjusted EBITDA $24.5M (+63.3% YoY); FY Adj EBITDA $67.2M, down 5.8% from $71.3M.
- DBMG (Infrastructure) backlog $1.8B, up from $1.1B a year ago; Q4 segment revenue $373.9M (+65.7%).
- R2 Life Sciences secured 600-system minimum purchase commitment in China; MediBeacon got FDA approval for next-gen TGFR.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006837/000100683726000013/0001006837-26-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006837/000100683726000013/vate-20260326.htm
  HTML page:      https://secwatch.observer/filing/0001006837-26-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer